S 004
Alternative Names: S004Latest Information Update: 28 Nov 2022
At a glance
- Originator Coeptis Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified in USA
- 03 Oct 2019 Clinical trials in Unspecified in USA (unspecified route) (Coeptis Pharmaceuticals pipeline, October 2019)
- 12 Dec 2018 Investigation in Unspecified in USA (unspecified route) (Coeptis Pharmaceuticals pipeline, December 2018)